Int Neurourol J.  2018 Mar;22(1):41-50. 10.5213/inj.1834996.498.

Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence

  • 1Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Russian Federation.
  • 2Department of Urology, City polyclinic No. 3, Vladivostok, Russian Federation.
  • 3Department of Functional Diagnostics, Med. Association No. 2 of Vladivostok, Vladivostok, Russian Federation.


The aim of this study was to investigate the safety and the effects of elevated doses of solifenacin and trospium on cognitive function and health-related quality of life (HRQoL) in elderly women receiving treatment for urinary incontinence.
The study included 312 women aged 60-83 years (mean age, 69.4 years). All participants had scored at least 24 points on the Mini-Mental State Examination (MMSE) scale, and all of them had been diagnosed with urge urinary incontinence (UUI) or mixed urinary incontinence (MUI). The women were randomly assigned to 3 groups: group A, individuals who were simultaneously administered solifenacin at a high dosage of 20 mg per day and trospium at a high dosage of 60 mg per day; group B, persons taking solifenacin and trospium at the usual dosage of 10 and 30 mg per day, respectively; and group C, persons who received a placebo. Participants' cognitive status was assessed by the MMSE, Controlled Oral Word Association Test, Wechsler Adult Intelligence Scale-Revised, Wechsler Memory Scale III, Colour Trails Test, and California Verbal Learning Test scales. The HRQoL assessment was performed using the Medical Outcomes Study 36-Item Health Survey.
The cognitive function parameters did not differ at the start and end of the study across the groups (P>0.05). Additionally, the cognitive function parameters did not differ significantly within each group between the start and end of the study (P>0.05). The values of most HRQoL parameters regarding the functional state of the lower urinary tract (LUT) after the termination of treatment significantly improved in groups A and B (P < 0.05). A significant correlation between cognitive status and HRQoL or LUT parameters was absent (r < 0.3), while the correlations between HRQoL and LUT parameters were r=0.31-0.83, P < 0.05.
The use of elevated doses of solifenacin and trospium did not increase the risk of cognitive impairment in women with UUI and MUI. The combination of solifenacin and trospium at a double dosage may be recommended to elderly women with treatment-resistant symptoms of UUI and MUI. However, the safety of combining antimuscarinic drugs in women with an increased volume of residual urine requires further study.


Muscarinic antagonists; Cognition disorders; Quality of life; Urinary incontinence

MeSH Terms

Cognition Disorders
Health Surveys
Muscarinic Antagonists
Quality of Life*
Solifenacin Succinate*
Urinary Incontinence*
Urinary Tract
Verbal Learning
Weights and Measures
Word Association Tests
Muscarinic Antagonists
Solifenacin Succinate
Full Text Links
  • INJ
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error